You have 3 free articles left this month. Get your free Basic subscription now and gain instant access to more.

Slovenia's Salus cons net profit declines 13.1% y/y in H1

Author Radomir Ralev
Slovenia's Salus cons net profit declines 13.1% y/y in H1 Author: Salus. License: All rights reserved.

LJUBLJANA (Slovenia), August 12 (SeeNews) - Slovenian pharmaceutical products wholesaler Salus [LJE:SALR] said its consolidated net profit declined to 6.4 million euro ($6.6 million) in the first half of 2022 from 7.4 million euro in the same period of last year.

Consolidated net sales revenue went up by an annual 13.7% to 247.4 million euro in the six-month period through June 2022, Salus said in a filing with the Ljubljana Stock Exchange on Thursday.

The company's operating profit decreased to 8.1 million euro from 9.3 million euro in January-June 2021, while EBITDA totalled 10.2 million euro, down from 10.5 million euro in the like period of last year.

Ljubljana-based Salus is one of Slovenia's leading wholesalers of pharmaceutical and medical products.

($ = 0.96701 euro)

 
Compare